Dr Elizabeth O’Donnell, MD, received her medical degree from the Vanderbilt University School of Medicine, Nashville, TN, qualifying in 2007. Dr O’Donnell completed her residency in internal medicine at the Beth Israel Deaconess Medical Center, Boston, MA, in 2010, followed by her fellowship in hematology/oncology at the Dana-Farber Cancer Institute, Boston, MA, in 2014.
Dr O’Donnell is currently the Director of Lifestyle Medicine and Associate Director of Survivorship as well as a Medical Oncologist in the Multiple Myeloma Disease Center, Massachusetts General Hospital, Boston, MA. She is also an Assistant Professor of Medicine at the Harvard Medical School, Boston, MA.
Speaking on novel multiple myeloma therapeutics
Dr O’Donnell’s primary research interest lies in the development of novel therapeutics for multiple myeloma. She has been actively involved in trials investigating targeted therapies like chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, particularly in the relapsed/refractory setting.
Dr O’Donnell is Principal Investigator for the Phase II study (NCT02833610) exploring the monoclonal antibody denosumab, and for a Phase II trial (NCT04430894) investigating the combination of carfilzomib, isatuximab, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.